Amendment No. 3 to Schedule 13D for Recursion Pharmaceuticals, Inc.

This filing serves as the final amendment to the Schedule 13D for Recursion Pharmaceuticals, Inc., marking an "exit filing" for the Reporting Persons. The amendment details changes in beneficial ownership of Class A Common Stock. Key events include the transfer of shares from MIC LP to MCAS on March 31, 2023. A significant transaction involved Recursion Pharmaceuticals acquiring Exscientia plc on November 20, 2024, through a scheme of arrangement. Following this, MIC Europe received 1,192,275 shares of common stock in exchange for its Exscientia shares. Between December 18, 2025, and the filing date, a total of 12,985,927 shares were sold, resulting in Mubadala and Mamoura ceasing to beneficially own any shares. As of the filing date, the Reporting Persons collectively own approximately 1.9% of the outstanding common shares, a decrease from approximately 5.9% as of November 20, 2024. The filing also includes a joint filing agreement among the reporting parties dated December 23, 2025.